Eli Lilly and Company (NYSE: LLY) has announced plans to significantly expand its domestic pharmaceutical manufacturing capabilities by investing over $50 billion since 2020, marking the largest such investment in U.S. history. The company intends to construct four new manufacturing sites in the United States this year, which will focus on active pharmaceutical ingredients (API) and injectable therapies. This expansion is expected to create 13,000 high-wage jobs in manufacturing and construction across America. “Lilly’s optimism about the potential of our pipeline across therapeutic areas drives our commitment to bolster domestic manufacturing,” said David A. Ricks, Lilly’s chair and CEO. The investment is anticipated to enhance local economies through increased spending, tax revenue, and infrastructure improvements. The company is currently negotiating with several states and expects to announce the locations of the new sites in 2025. — news from Investors | Eli Lilly and Company
